TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12847368

Group type: EXPERIMENTAL
Intervention: Budesonide foam
Number of subjects: 251

Group type: COMPARATOR
Intervention: Hydrocortisone foam
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Budesonide foam (subgroup of non-responders to mesalamine)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Hydrocortisone foam (subgroup of non-responders to mesalamine)
Number of subjects: 251
Study: 10385012

Group type: EXPERIMENTAL
Intervention: BacT/Alert FAN bottle
Number of subjects: 945

Group type: COMPARATOR
Intervention: BacT/Alert STD bottle
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: BacT/Alert system
Number of subjects: 945

Group type: COMPARATOR
Intervention: ISO tube
Number of subjects: 945
Study: 9032580

Group type: EXPERIMENTAL
Intervention: Flosulide (20 mg twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 19
Study: 1442478

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 100
Study: 4066373

Group type: EXPERIMENTAL
Intervention: Mitomycin instillation therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no mitomycin treatment)
Number of subjects: 95
Study: 30607812

Group type: EXPERIMENTAL
Intervention: Reading comprehension intervention
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Writing intervention (teacher-led computer-supported)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Focus group interviews and observations
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Artifact review of school curricula and PD plans
Number of subjects: 280
Study: 29589328

Group type: EXPERIMENTAL
Intervention: Thrombolytic removal of obstructive IVH using external ventricular drainage
Number of subjects: 500
Study: 26970753

Group type: EXPERIMENTAL
Intervention: Participatory approach implementation strategy including working group meetings, supervisor training, and optional coaching.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Working group meetings and supervisor training.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Coaching for supervisors (optional).
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall implementation strategy.
Number of subjects: 116
Study: 25269022

Group type: EXPERIMENTAL
Intervention: Acamprosate and naltrexone
Number of subjects: 74
Study: 22370004

Group type: EXPERIMENTAL
Intervention: Usual care plus a cognitive behaviour therapy (CBT) booklet (BUC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded exercise therapy (GET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counselling (COUNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GET
Number of subjects: 0

Group type: COMPARATOR
Intervention: COUNS
Number of subjects: 0
Study: 19888202

Group type: EXPERIMENTAL
Intervention: Stool form (Bristol Stool Scale)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Bristol stool form value <3
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Stool frequency
Number of subjects: 110
Study: 17956953

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (individualized dose titration regimen)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (fixed body weight-based dosing regimen)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (both dosing regimens combined)
Number of subjects: 29
Study: 16160131

Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (79.2 Gy)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Conventional-dose radiation therapy (70.2 Gy)
Number of subjects: 393
Study: 12100367

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneously once daily)
Number of subjects: 212

Group type: COMPARATOR
Intervention: UFH (5000 IU subcutaneously thrice daily)
Number of subjects: 212
Study: 10439108

Group type: EXPERIMENTAL
Intervention: CPAP at 4 cm H2O
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP at 7 cm H2O
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O
Number of subjects: 0
Study: 8555803

Group type: EXPERIMENTAL
Intervention: Levodopa and dopa decarboxylase inhibitor (arm 1)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Levodopa and decarboxylase inhibitor in combination with selegiline (arm 2)
Number of subjects: 520
Study: 2355103

Group type: EXPERIMENTAL
Intervention: labetalol (100 mg bid)
Number of subjects: 34

Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) (25 mg bid)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 34

Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Number of subjects: 34
Study: 872445

Group type: EXPERIMENTAL
Intervention: Long-term diphenylhydantoin (DPH) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of DPH treatment
Number of subjects: 0
Study: 30927200

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program for 16 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: No change in regular physical activity (control group)
Number of subjects: 39
Study: 30056040

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Limited resection vs full resection
Number of subjects: 752
Study: 28885425

Group type: EXPERIMENTAL
Intervention: 10-mL 1% lidocaine paracervical nerve block
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sham block (1 cm depression of the vaginal epithelium at paracervical block sites with a wooden cotton-tipped applicator)
Number of subjects: 95
Study: 25845406

Group type: EXPERIMENTAL
Intervention: Vagisan(®) Moisturising Cream (CREAM)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Non-hormonal vaginal gel (GEL)
Number of subjects: 117
Study: 23273638

Group type: EXPERIMENTAL
Intervention: Tualang honey (3 mls intraoperatively, followed by 4 mls orally three times daily for seven days) + Sultamicillin (25mg/kg IV three times daily for two days, then orally twice daily for five days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sultamicillin (25mg/kg IV for two days, then orally twice daily for five days)
Number of subjects: 63
Study: 20084368

Group type: EXPERIMENTAL
Intervention: 25 mg MDMA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg MDMA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18056887

Group type: EXPERIMENTAL
Intervention: Educational program (multifaceted including an interactive meeting, a leaflet, a website, and a consultation with the diabetes care provider)
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 1124
Study: 16171020

Group type: EXPERIMENTAL
Intervention: Topical application of 25% metronidazole-containing mucoadhesive lipogel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control pockets (not treated with metronidazole)
Number of subjects: 25
Study: 12849803

Group type: EXPERIMENTAL
Intervention: Embryo selection based on sequential evaluation of both pronuclear morphology and embryo morphology on day 3
Number of subjects: 441

Group type: COMPARATOR
Intervention: Embryo selection based on only pronuclear morphology
Number of subjects: 441

Group type: COMPARATOR
Intervention: Embryo selection based on only day‐3 embryo morphology
Number of subjects: 441
Study: 10383498

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, and amoxycillin 1000 mg (OAC)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 250 mg, and metronidazole 400 mg (OMC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily (O)
Number of subjects: 160
Study: 8754956

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1817620

Group type: EXPERIMENTAL
Intervention: Mapleson D system (Bain) with 4 litre of oxygen per minute for 3 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triservice Anaesthetic Apparatus (TSA)
Number of subjects: 0
Study: 7048776

Group type: EXPERIMENTAL
Intervention: 0.5% 5-fluorouracil (5-FU) salicylic acid containing varnish
Number of subjects: 59

Group type: COMPARATOR
Intervention: Varnish without 5-FU (placebo)
Number of subjects: 59
Study: 28002986

Group type: EXPERIMENTAL
Intervention: Copper supplementation (1000 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27157472

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate (LC) diet
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 118
Study: 24817294

Group type: EXPERIMENTAL
Intervention: Hospital-based calisthenic exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based calisthenic exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 40
Study: 22308301

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 2774

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 2774
Study: 20942287

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints compound general anesthesia (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture at non‐acupoints compound general anesthesia (group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia (group A)
Number of subjects: 90
Study: 18380632

Group type: EXPERIMENTAL
Intervention: Warfarin arm of SPORTIF III
Number of subjects: 381
Study: 16253496

Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 14636097

Group type: EXPERIMENTAL
Intervention: 30% of 1 repetition maximum (n = 9)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80% of 1 repetition maximum (n = 9)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 24
Study: 10917401

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 to 200 mg/day) combined with neuroleptics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neuroleptics only
Number of subjects: 30
Study: 8702053

Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) infusion (20 ng/kg bw/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) infusion
Number of subjects: 9
Study: 1687130

Group type: EXPERIMENTAL
Intervention: Formoterol (6, 18 and 54 micrograms)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol (100, 300 and 900 micrograms)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 mg Salbutamol (after last dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between Formoterol and Salbutamol
Number of subjects: 9
Study: 6395349

Group type: EXPERIMENTAL
Intervention: Furapyrimidone
Number of subjects: 218

Group type: COMPARATOR
Intervention: Hetrazan
Number of subjects: 218
Study: 30883497

Group type: EXPERIMENTAL
Intervention: 12 weeks of trunk-specific exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Education (control group)
Number of subjects: 24
Study: 29851804

Group type: EXPERIMENTAL
Intervention: Video narratives intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard patient education care (Control)
Number of subjects: 200
Study: 26782254

Group type: EXPERIMENTAL
Intervention: Chemotherapy with primary tumor resection (PTR)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 480
Study: 25007865

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg and 200 μg once daily
Number of subjects: 0
Study: 22377389

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: varenicline-placebo
Number of subjects: 0
Study: 21055090

Group type: EXPERIMENTAL
Intervention: Standardized dust mite allergen specific immunotherapy (SIT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (control group)
Number of subjects: 85
Study: 17334147

Group type: EXPERIMENTAL
Intervention: Tap water irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 0
Study: 15802694

Group type: EXPERIMENTAL
Intervention: Graded exercise
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 105
Study: 12766091

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10559514

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of LNMMA (8 and 16 micromol/min) followed by intracoronary administration of 250 mcg nitroglycerin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intracoronary infusion of LNMMA
Number of subjects: 30
Study: 8565164

Group type: EXPERIMENTAL
Intervention: OPC-18790 (5 micrograms.kg‐1.min‐1, low dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: OPC-18790 (10 micrograms.kg‐1.min‐1, high dose)
Number of subjects: 17
Study: 1683557

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 448
Study: 6129869

Group type: EXPERIMENTAL
Intervention: Terfenadine 20 mg 3 times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate 4 mg 3 times a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terfenadine (up to 200 mg 3 times a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 30
Study: 31864496

Group type: EXPERIMENTAL
Intervention: Stripping twice before testicular tissue collection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stripping once
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Testicular tissue collection combined with stripping
Number of subjects: 20
Study: 30968801

Group type: EXPERIMENTAL
Intervention: Host plant cultivar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parasitism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Host-plant-adapted aphid species
Number of subjects: 0
Study: 30177462

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Everolimus (BV + EV)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bevacizumab alone (BV)
Number of subjects: 150
Study: 27090299

Group type: EXPERIMENTAL
Intervention: Future Care Planning (FCP) for 12 weeks upon discharge
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Future Care Planning (FCP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care for 12 weeks upon discharge
Number of subjects: 50
Study: 25165723

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 20
Study: 23297562

Group type: EXPERIMENTAL
Intervention: sidong wubu method for 6 months
Number of subjects: 654

Group type: COMPARATOR
Intervention: open reduction and internal fixation (control group)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: sidong wubu method
Number of subjects: 654
Study: 18815772

Group type: EXPERIMENTAL
Intervention: 1 mg nicotine via nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo via nasal spray
Number of subjects: 0
Study: 17804334

Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement (ZPC)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Copper bands cemented with ZPC
Number of subjects: 176

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 176

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 176
Study: 16035374

Group type: EXPERIMENTAL
Intervention: Probiotic multivitamin and mineral supplement (verum)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 11986138

Group type: EXPERIMENTAL
Intervention: Clinic-based skills training supplemented with manual-based generalization sessions in the community
Number of subjects: 63

Group type: COMPARATOR
Intervention: Clinic-based skills training alone
Number of subjects: 63
Study: 9661595

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (mid and high doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen (late pubertal dose)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7715103

Group type: EXPERIMENTAL
Intervention: Resting MIBG SPECT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Resting BMIPP SPECT
Number of subjects: 49

Group type: COMPARATOR
Intervention: Exercise Tl SPECT
Number of subjects: 49

Group type: COMPARATOR
Intervention: Resting Tl SPECT
Number of subjects: 49
Study: 2655812

Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg, 2 to 5 tablets twice a week for 1 year)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 297
Study: 332218

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30895578

Group type: EXPERIMENTAL
Intervention: Early diabetes testing (HBA1c, 50 g glucose challenge test, or 100 g oral glucose tolerance test) before 24 weeks
Number of subjects: 2698

Group type: EXPERIMENTAL
Intervention: Early diabetes testing
Number of subjects: 2698
Study: 31494015

Group type: EXPERIMENTAL
Intervention: Positive Minds-Strong Bodies (PMSB) intervention
Number of subjects: 307

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 307
Study: 28344197

Group type: EXPERIMENTAL
Intervention: OM3-CA administered after a meal
Number of subjects: 42

Group type: COMPARATOR
Intervention: OM3-CA administered in fasting conditions
Number of subjects: 42

Group type: COMPARATOR
Intervention: OM3-CA administered before a meal
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Before meal condition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: After meal condition
Number of subjects: 42
Study: 26447705

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) with local anesthetic and saline, three 120 second cycles per targeted nerve
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Steroid injections with local anesthetic mixed with deposteroid and 3 rounds of sham PRF
Number of subjects: 81
Study: 23643652

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) in advanced to 50% of maximum protrusion (A50) position for 1 week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) for snorers (n=8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) for headache assessment
Number of subjects: 16
Study: 21277403

Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 261

Group type: COMPARATOR
Intervention: Non-vaccinated controls
Number of subjects: 261
Study: 19808130

Group type: EXPERIMENTAL
Intervention: ARF15 BID (15 microg/2 mL twice daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ARF30 QD (30 microg/4 mL once daily)
Number of subjects: 33
Study: 16394955

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (750 mg daily for 10 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15700504

Group type: EXPERIMENTAL
Intervention: Concurrent smoking intervention (during alcohol treatment)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Delayed smoking intervention (6 months later)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Concurrent smoking intervention
Number of subjects: 499

Group type: COMPARATOR
Intervention: Delayed smoking intervention
Number of subjects: 499
Study: 11711507

Group type: EXPERIMENTAL
Intervention: Alcohol reduction
Number of subjects: 2234

Group type: COMPARATOR
Intervention: Control group (no alcohol reduction)
Number of subjects: 2234
Study: 9161369

Group type: EXPERIMENTAL
Intervention: Concentric (CON) isokinetic measurements at 60 degrees/sec and 180 degrees/sec
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) isokinetic measurements at 60 degrees/sec and 180 degrees/sec
Number of subjects: 16

Group type: COMPARATOR
Intervention: Menstrual cycle phases (MP, FP, LP)
Number of subjects: 16
Study: 7956548

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 5980

Group type: COMPARATOR
Intervention: Spontaneous onset of labor (Control)
Number of subjects: 5980
Study: 2953527

Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) inhalation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Histamine inhalation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ipratropium bromide pretreatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cimetidine and mepyramine or indomethacin pretreatment
Number of subjects: 33
Study: 31225688

Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 60
Study: 29354988

Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation) for 30 min at bilateral Zusanli (ST 36) and Neiguan (PC 6) with frequency of 5 Hz and intensity 1 mA lower than tolerance threshold.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham group (stimulated at the same acupoints with current intensity 1 mA lower than sensory threshold).
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 75
Study: 26271173

Group type: EXPERIMENTAL
Intervention: 13-valent polysaccharide conjugate vaccine (PCV13)
Number of subjects: 84496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84496
Study: 23595153

Group type: EXPERIMENTAL
Intervention: Full-dose twice-daily nevirapine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Nevirapine dose-escalation
Number of subjects: 162